A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
Ilson David H,
Levine Douglas A,
Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in patients with previously treated esophageal cancer.